449 related articles for article (PubMed ID: 15314658)
1. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ
PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658
[TBL] [Abstract][Full Text] [Related]
2. p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis.
Ruddell A; Kelly-Spratt KS; Furuya M; Parghi SS; Kemp CJ
Oncogene; 2008 May; 27(22):3145-55. PubMed ID: 18059331
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
Lin AW; Lowe SW
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
[TBL] [Abstract][Full Text] [Related]
4. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.
Tolbert D; Lu X; Yin C; Tantama M; Van Dyke T
Mol Cell Biol; 2002 Jan; 22(1):370-7. PubMed ID: 11739748
[TBL] [Abstract][Full Text] [Related]
5. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
[TBL] [Abstract][Full Text] [Related]
6. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
Russell JL; Weaks RL; Berton TR; Johnson DG
Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
[TBL] [Abstract][Full Text] [Related]
7. Tumor spectrum in ARF-deficient mice.
Kamijo T; Bodner S; van de Kamp E; Randle DH; Sherr CJ
Cancer Res; 1999 May; 59(9):2217-22. PubMed ID: 10232611
[TBL] [Abstract][Full Text] [Related]
8. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
[TBL] [Abstract][Full Text] [Related]
9. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.
Bardeesy N; Aguirre AJ; Chu GC; Cheng KH; Lopez LV; Hezel AF; Feng B; Brennan C; Weissleder R; Mahmood U; Hanahan D; Redston MS; Chin L; Depinho RA
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5947-52. PubMed ID: 16585505
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.
Inoue K; Wen R; Rehg JE; Adachi M; Cleveland JL; Roussel MF; Sherr CJ
Genes Dev; 2000 Jul; 14(14):1797-809. PubMed ID: 10898794
[TBL] [Abstract][Full Text] [Related]
11. Sumoylation induced by the Arf tumor suppressor: a p53-independent function.
Tago K; Chiocca S; Sherr CJ
Proc Natl Acad Sci U S A; 2005 May; 102(21):7689-94. PubMed ID: 15897463
[TBL] [Abstract][Full Text] [Related]
12. PTEN ablation in Ras(Ha)/Fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition.
Macdonald FH; Yao D; Quinn JA; Greenhalgh DA
Oncogene; 2014 Aug; 33(32):4132-43. PubMed ID: 24037529
[TBL] [Abstract][Full Text] [Related]
13. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice.
Eischen CM; Rehg JE; Korsmeyer SJ; Cleveland JL
Cancer Res; 2002 Apr; 62(7):2184-91. PubMed ID: 11929842
[TBL] [Abstract][Full Text] [Related]
14. Independent genetic control of early and late stages of chemically induced skin tumors in a cross of a Japanese wild-derived inbred mouse strain, MSM/Ms.
Okumura K; Sato M; Saito M; Miura I; Wakana S; Mao JH; Miyasaka Y; Kominami R; Wakabayashi Y
Carcinogenesis; 2012 Nov; 33(11):2260-8. PubMed ID: 22843548
[TBL] [Abstract][Full Text] [Related]
15. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1).
Obata M; Imamura E; Yoshida Y; Goto J; Kishibe K; Yasuda A; Ogawa K
Mol Carcinog; 2001 Sep; 32(1):9-18. PubMed ID: 11568971
[TBL] [Abstract][Full Text] [Related]
16. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype.
King D; Yang G; Thompson MA; Hiebert SW
Oncogene; 2002 Jul; 21(32):4978-82. PubMed ID: 12118376
[TBL] [Abstract][Full Text] [Related]
17. p19ARF-induced p53-independent apoptosis largely occurs through BAX.
Suzuki H; Kurita M; Mizumoto K; Nishimoto I; Ogata E; Matsuoka M
Biochem Biophys Res Commun; 2003 Dec; 312(4):1273-7. PubMed ID: 14652011
[TBL] [Abstract][Full Text] [Related]
18. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia.
Bardeesy N; Morgan J; Sinha M; Signoretti S; Srivastava S; Loda M; Merlino G; DePinho RA
Mol Cell Biol; 2002 Jan; 22(2):635-43. PubMed ID: 11756558
[TBL] [Abstract][Full Text] [Related]
19. Gain of function in the mouse model of a recurrent mutation p53
Zhao L; Wang B; Zhao X; Wu X; Zhang Q; Wei C; Shi M; Li Y; Tang W; Zhang J; Yang J; Singh SK; Jia S; Luo Y
Mol Carcinog; 2018 Feb; 57(2):147-158. PubMed ID: 28949402
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppression by p53 in the absence of Atm.
Bailey SL; Gurley KE; Hoon-Kim K; Kelly-Spratt KS; Kemp CJ
Mol Cancer Res; 2008 Jul; 6(7):1185-92. PubMed ID: 18583527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
